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Objective: To assess the economic impact of the introduction of DuoResp Spiromax by focus-
ing on a potential improvement in the inhalation technique to strengthen medication adherence 
for the treatment of moderate to severe asthmatics in Spain and five Spanish regions including 
Andalusia, Catalonia, Galicia, Madrid, and Valencia.
Methods: A 4-year budget impact model was developed for the period 2015–2018 from the 
Spanish Healthcare System perspective. Budesonide–formoterol fixed-dose combination deliv-
ered by Turbuhaler was considered to be the most appropriate comparator for assessing the 
budget impact with the introduction of DuoResp Spiromax. National and regional data on 
asthma prevalence were obtained from the literature. Input parameters on health care resources 
were obtained by consulting experts from different Spanish hospitals. Resources used included 
medical visits, emergency room visits, and hospitalizations. The average numbers of primary 
care and specialist visits per year were also gathered. Based on health care resource use per 
patient, the total treatment cost per patient was estimated.
Results: The population with moderate to severe asthma treated with budesonide–formoterol 
fixed-dose combinations delivered by Turbuhaler in 2015 was estimated to be 166,985 in Spain. 
Region-specific prevalence data resulted in 25,081, 12,392, 16,097, 17,829, and 15,148 patients 
in Andalusia, Catalonia, Galicia, Madrid, and Valencia, respectively. Based on the forecast uptake 
of DuoResp Spiromax, the total budget savings in Spain were expected to be €1.509 million 
over the next 4 years. Region-specific rates imply that the total savings were expected to be 
€229,706 in Andalusia, €90,145 in Catalonia, €188,327 in Galicia, €122,669 in Madrid, and 
€165,796 in Valencia over 2015–2018.
Conclusion: The introduction of DuoResp Spiromax, which represents a potential improve-
ment in the inhalation technique to strengthen medication adherence for the treatment of 
moderate to severe asthma, could represent savings for the Spanish National Health Society 
and five Spanish regions.
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Introduction
Asthma is a leading cause of morbidity, mortality, and 
economic burden and a significant public health problem 
worldwide.1,2 This chronic condition is characterized by inflam-
mation of respiratory airways, hypersensitivity of airway path, 
and variable airflow limitation for short periods of time.
Daily medication is used to prevent or improve asthma 
symptoms. Inhaler therapy for asthma delivers therapeutic 
drug doses into the airways, leading to local efficacy within the 
lungs.3 Effective use of inhaler requires proper inhalation tech-
nique, which implies a good medication adherence, because it 
is a critical factor of self-management of the disease. Dry pow-
der inhalers (DPIs) overcome the difficulties between inhaler 
actuation and inspiration, one of the most common errors with 
pressurized metered dry power; however, recent reviews have 
shown that misuse of DPIs is also common in real life.4,5
There are factors such as low inhaler complexity and 
patient preferences that can help to optimize the inhaler 
device by improving adherence to medication.6 Strengthening 
these factors would contribute to good disease management 
and better use of health care resources, given the excessive 
costs required to treat chronic obstructive lung diseases.
Asthma is a significant public health problem among 
inner city populations. In Spain, asthma prevalence varies 
widely, and studies have shown that divergence is explained 
by genetic factors, proportion of immigrants, and environ-
mental, organizational, and health care factors of regional 
health care services.7 It has been reported that half of the 
treated patients do not comply correctly with their treat-
ment.8 Medication adherence is a key factor for controlling 
progression of chronic disease.
The lack of adherence is associated with increased health 
care costs due to emergency room visits and hospitalizations 
as well as additional diagnostic tests and stepping up therapy 
compared to the original less costly therapy, which also indi-
cates higher consumption of primary care (PC) and specialist 
consultations.5,9 Given the developments in inhalation devices 
such as pressurized metered dry powder and DPI, one would 
expect that these imply better clinical outcomes; however, 
most of the current inhalers are often poorly used and are not 
intuitive, which implies that an extensive training is needed 
in the long term.10,11 Therefore, optimization of the inhaler 
device needs to be oriented to meet the current unmet needs 
associated with medication adherence in the management of 
obstructive lung disease.
In the current study, we evaluated the expected economic 
impact from the increase in the market share of Spiromax, a 
brand-new inhalation device, for the maintenance therapy with 
budesonide–formoterol fixed-dose combination (FDC), by 
using a budget impact model. This new inhalation device has 
been shown to reduce common utilization errors such as dose 
preparation errors, adequate flow rates, and even environmental 
conditions that might limit the delivery of the drug directly to 
the lungs.12 We included data from the perspective of the Span-
ish Healthcare System (NHS) as well as regional data from 
five Spanish Autonomous Communities (hereafter known as 
regions): Andalusia, Catalonia, Galicia, Madrid, and Valencia.
Methods
Model development and structure
According to legislation of scientific studies (SAS/3470/2009 
Order of December 16, to make public guidelines on post-
authorization studies that are observational for drugs for 
human use) this project did not require approval from an 
ethical review board as we did not have access to patient 
level data, we did not need to interview patients to obtain 
estimates, and this was not a clinical study. The budget 
impact model was developed in Microsoft Excel from 
the perspective of the Spanish NHS, and for this purpose 
a time horizon of 4 years (2015–2018) was used. Spain 
and five Spanish regions were included in our analysis. 
Budesonide–formoterol FDCs delivered by Turbuhaler 
whose complete brand names can be Rilast Turbuhaler 
and Symbicort Turbuhaler were considered to be the most 
appropriate comparator for assessing the budget impact with 
the introduction of DuoResp Spiromax, a new inhaler 
for delivering budesonide– formoterol FDC. We decided 
to compare these two different inhalation devices that 
delivered budesonide–formoterol FDC because changes in 
prescription regimens were not hypothesized in this study.
Input parameters were obtained by expert panel consulta-
tion from different Spanish hospitals. Therefore, the model 
analyzed health care resource utilization per patient based on 
their daily maintenance treatment for asthma and the number 
of days with events such as hospitalizations and visits to the 
emergency room, PC visits, and specialist visits. All cost 
estimates were reported in Euros (EUR 2015), and a discount 
rate of 3% was applied.
It is worth mentioning that during the time this study was 
being completed, there was a significant change in prices 
of the drugs included in this analysis. From October 2015 
onward, prices of both drugs were set at the same level by 
the Spanish Ministry of Health; therefore, price effect was 
no longer useful to calculate the economic impact of the 
introduction of DuoResp Spiromax.13
This model included diagnosed patients who control 
asthma with a maintenance therapy. Proportion of FDC of 
budesonide–formoterol utilization that was delivered by 
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a DPI was based on the national and regional sales data 
for Spain reported by IMS. Therefore, data on Symbicort 
Turbuhaler and Rilast Turbuhaler utilization were used 
to estimate the target population. Forecast of DuoResp 
Spiromax uptake rates was reported by Teva Pharma.
The model generated estimates for the costs per patient 
and the total direct costs of treatment including drug and med-
ical cost based on market shares and other input  parameters. 
The potential effect of a strengthening of adherence to the 
total costs of asthma was generated from savings in medical 
resources utilization associated with an improvement in the 
inhalation technique. All patients were assumed to receive 
treatment during the whole year.
Model input variables
Target population
To estimate the target population diagnosed with a main-
tenance therapy with budesonide–formoterol FDC, the 
following algorithm was applied, as shown in Figure 1. A 
literature review was performed to identify the prevalence 
of asthma among the adult population of Spain and regions 
included in this analysis.14–17 Estimates for asthma were 
extrapolated to the adult populations obtained from the 
population projections conducted by the National Institute of 
Statistics (INE).18 We had to take into account that >50% of 
asthmatic patients are not diagnosed and 26% of those do not 
receive treatment.19 A percentage was applied to distinguish 
patients using an FDC and among these patients, those who 
take budesonide–formoterol FDC delivered by DPI were 
determined.20 The proxy for capturing these patients was the 
percentage of patients using Symbicort/Rilast Turbuhaler.
Inhalation technique, medication 
adherence, medical resource utilization, 
and costs
Before identifying directly variations in health care resources 
associated with the use of each inhaler, experts were asked 
to specify percentage of utilization errors with Spiromax 
and Turbuhaler, and the differences between use of inhala-
tion devices were mainly those regarding the incorrect dose 
loading and keeping the inhaler inclined not >45° from the 
vertical axis (Table 1). These results were not used for cal-
culations, but they were relevant to confirm that the misuse 
of inhaler is seen in clinical practice.
Obtaining input data on health care resource utilization 
associated with potential strengthening of adherence was 
the basis to estimate the economic consequences of the 
introduction of Spiromax in Spain. The use of health care 
resources was estimated based on data from clinical practice 
by consulting a panel of five clinical experts in pneumology, 
allergy, and a general practitioner from different Spanish 
hospitals. Accordingly with our expert panel, the proportions 
of patients who visit the emergency room and those who are 
hospitalized due to suboptimal inhalation are estimated to 
be 6.96% and 2.64%, respectively. Among these patients we 
also observed whether there were differences in the number 
of these events between patients using Turbuhaler versus 
patients using Spiromax (Table 2).
Figure 1 Target population of the study.
Notes: Asthma prevalence: Spain 9.90%, Andalusia 9.90%, Catalonia 5.60%, Galicia 
12.90%, Madrid 7.00%, Valencia 9.80%; region-specific % of patients who are treated 
with Rilast–Symbicort Turbuhaler: Spain 34.99%, Andalusia 33.35%, Catalonia 
31.53%, Galicia 34.97%, Madrid 36.46%, and Valencia 34.26% of patients who are 
treated with a fixed-dose combination: Spain 35.85%, Andalusia 31.23%, Catalonia 
33.42%, Galicia 42.86%, Madrid 38.17%, and Valencia 31.64%.
Total adult population
>18
Asthma prevalence
% of diagnosed patients
% of patients who are 
treated
with a FDC
Region-specific % of 
patients
who are treated with
Rilast®/Symbicort® 
Turbuhaler®
Adult population with asthma
in Spain
Adult population diagnosed
with asthma
Population with diagnosed asthma
that receives fixed-dose
 combination (FDC) therapy
Target population that receives
formoterol–budesonide FDC
delivered by a dry powder
 inhaler (DPI)
Table 1 Errors observed in daily practice 
Checklist of inhalation 
technique errors
% of patients using 
Symbicort/Rilast 
Turbuhaler
% of patients 
using DuoResp 
Spiromax
Failure of loading 17.17 0.83
No breath holding after 
inhalation
37.00 36.67
Keep the inhaler inclined 
not >45° from the vertical 
axis during loading
22.33 5.83
No exhale prior to inhale 35.83 28.67
Stop inhaling prematurely 27.67 22.50
Exhaling into the device 
mouthpiece after inhalation
12.17 8.83
Note: These percentages were not used for calculation. Estimates were sourced 
from a clinical expert panel of pneumologists, allergists, and a general practitioner 
and were prepared by the authors.
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Regarding number of PC visits and specialist visits, it 
was not possible to obtain a direct percentage of visits due 
to problems with the inhalers. One visit to a PC provider 
can be used to solve various patients’ concerns, includ-
ing problems with the device. Thus, it was necessary to 
ask the overall number of PC and specialist visits that a 
regular asthmatic patient has. On average patients who 
used Turbuhaler should not be different from those using 
Spiromax because they share indication with the same FDC 
of budesonide– formoterol.21 Therefore, we assume that this 
variation between health care resource utilization associated 
with Spiromax versus Turbuhaler might be related to the 
inhalation device (Table 2). Given that there is no scientific 
literature published on this topic, experts’ consultation was 
needed to obtain input data on health care resource utiliza-
tion. Monitoring test and its cost were also included in the 
model. This information was used to calculate the costs for 
medical resources associated with each drug.
Costs of health care resources included in this analysis 
were obtained from regional tariff lists.22–33 Cost of health care 
resources at the national level are the mean of 12 regions, 
including those in this analysis.
Budgetary impact analysis
Based on the annual drug cost and health care resource 
use per patient, the total treatment cost per patient was 
estimated in EUR 2015. With the annual average cost per 
patient for each treatment option, the target population, and 
the market shares for budesonide–formoterol FDC delivered 
by Turbuhaler, the overall economic impact of the mainte-
nance treatment of asthma for 2015–2018 was obtained. In 
the base case scenario or current scenario, a market without 
Table 2 Input data on drug cost, medical resource utilization, unit costs, and average cost per patient per year in Euro (€) 2015
Symbicort 
Turbuhaler
Rilast 
Turbuhaler
DuoResp 
Spiromax
Mean of regional 
unit costs in € 2015a
Annual resources of medical resource
Medical visits
Average number of PC visits per patient per year 4.80 4.80 4.60 52.62
Average number of specialist physician visits per 
patient per year
2.00 2.00 2.00 75.15
Average number of emergency visits per patient per 
year
0.014 0.014 0.014 173.31
Hospital resource utilization
Average number of hospitalization per patient per 
yearb
0.003 0.003 0.003 492.39
Average days of length of stay per patient per year 3.60 3.60 2.80 –
Other interventions
Average number of spirometries per patient per year 3.5 3.5 3.5 31.69
Average number of thorax radiography per patient 
per year
1.3 1.3 1.3 20.98
Total healthcare cost per patient per year
Drug cost (€)c 221 221 219 –
Cost of medical visits (€) 405 405 395 –
Cost of hospital resource utilization (€)b 5 5 4 –
Cost of other interventions (€) 138 138 138 –
Cost per patient (€) 769 769 756 –
Notes: aMean of unit costs of 12 Spanish regions. Region-specific unit costs of health care resources were used to estimate economic impact for five regions included. bThe 
proportions of patients who visit the emergency room and those who are hospitalized due to suboptimal inhaler utilization are 6.96% and 2.64%, respectively. Among patients 
who visited the emergency room we observed that on average the number of these events with Turbuhaler were 0.2 and with Spiromax were 0.2, which result in 0.014 
times €173.71. We performed same calculations with number of hospitalizations, which resulted in 0.003 times €492.39. cDifferences in drug cost are due to differences in 
distributions of doses. However, drug cost was not associated with adherence, so this variation was offset for calculation of adherence effect. Data is sourced from a clinical 
expert panel of pneumologists, allergists, and a general practitioner and were prepared by the authors.
Abbreviation: PC, primary care.
Table 3 Distribution of treatments (%): base case analysis and 
alternative scenario
Year
2015 2016 2017 2018
Base case analysis
Symbicort Turbuhaler 50.00% 50.00% 50.00% 50.00%
Rilast Turbuhaler 50.00% 50.00% 50.00% 50.00%
DuoResp Spiromax 0% 0% 0% 0%
Alternative scenario
Symbicort Turbuhaler 44.50% 41.00% 39.00% 37.50%
Rilast Turbuhaler 44.50% 41.00% 39.00% 37.50%
DuoResp Spiromax 11.00% 18.00% 22.00% 25.00%
Note: Data provided by Teva Pharma and it was prepared by the authors 
(unpublished data, 2015).
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DuoResp Spiromax was estimated. The current scenario 
was compared with an alternative in which the economic 
impact was calculated by taking into account DuoResp 
Spiromax and its potential effects toward improved medica-
tion adherence. The budget impact model was based on dif-
ferences between a scenario without DuoResp Spiromax, 
current scenario, and an alternative scenario (Table 3). The 
uptake of DuoResp Spiromax increases during the period 
of study.
Results
In our model, region-specific prevalence data were used, 
which vary across all five regions. Prevalence of asthma in 
Spain (9.90%) differs substantially from Catalonia (5.60%), 
Table 4 Target population (n) for asthma treatment
Year
Target population 2015 2016 2017 2018
Spain
Adult patients with asthma 3,748,190 3,726,486 3,705,397 3,686,296
Adult patients who are diagnosed and treated 1,331,357 1,323,648 1,316,157 1,309,373
Adult patients treated with an FDC 477,289 474,526 471,840 469,408
Adult patients treated with budesonide–formoterol delivered by a DPI 166,985 166,018 165,078 164,227
Andalusia
Adult patients with asthma 667,977 668,182 668,377 668,753
Adult patients who are diagnosed and treated 237,266 237,338 237,407 237,541
Adult patients treated with an FDC 74,093 74,116 74,137 74,179
Adult patients treated with budesonide–formoterol delivered by a DPI 25,081 25,089 25,096 25,110
Catalonia
Adult patients with asthma 331,090 326,955 323,031 319,444
Adult patients who are diagnosed and treated 117,603 116,134 114,741 113,466
Adult patients treated with an FDC 39,302 38,811 38,345 37,919
Adult patients treated with budesonide–formoterol delivered by a DPI 12,392 12,237 12,090 11,956
Galicia
Adult patients with asthma 302,391 300,709 299,044 297,444
Adult patients who are diagnosed and treated 107,409 106,812 106,220 105,652
Adult patients treated with an FDC 46,033 45,777 45,523 45,280
Adult patients treated with budesonide–formoterol delivered by a DPI 16,097 16,007 15,918 15,833
Madrid
Adult patients with asthma 360,702 358,131 355,641 353,387
Adult patients who are diagnosed and treated 128,121 127,208 126,324 125,523
Adult patients treated with an FDC 48,902 48,554 48,216 47,911
Adult patients treated with budesonide–formoterol delivered by a DPI 17,829 17,702 17,579 17,468
Valencia
Adult patients with asthma 393,305 389,855 386,517 383,421
Adult patients who are diagnosed and treated 139,702 138,476 137,291 136,191
Adult patients treated with an FDC 44,207 43,820 43,444 43,096
Adult patients treated with budesonide–formoterol delivered by a DPI 15,148 15,015 14,886 14,767
Abbreviations: FDC, fixed-dose combination; DPI, dry powder inhaler.
Table 5 Results of the base case budget impact analysis in Euro 2015 (€)
Year
2015 2016 2017 2018 Present value
Spain Current scenario
Symbicort Turbuhaler 64,210,549 65,753,902 69,363,528 75,404,694 262,437,044
Rilast Turbuhaler 64,210,549 65,753,902 69,363,528 75,404,694 262,437,044
Total cost 128,421,098 131,507,804 138,727,057 150,809,389 524,874,089
Alternative scenario
Symbicort Turbuhaler 57,147,388 53,918,199 54,103,552 56,553,521 212,247,425
Rilast Turbuhaler 57,147,388 53,918,199 54,103,552 56,553,521 212,247,425
DuoResp Spiromax 13,913,892 23,315,439 30,061,000 37,135,388 98,869,759
Total cost 128,208,670 131,151,839 138,268,105 150,242,430 523,364,611
Budget impact savings
-212,428 -355,965 -458,952 -566,959 -1,509,479 
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Year
2015 2016 2017 2018 Present value
Andalusia Current scenario
Symbicort Turbuhaler 10,157,509 10,465,439 11,106,022 12,142,679 41,898,894
Rilast Turbuhaler 10,157,509 10,465,439 11,106,022 12,142,679 41,898,894
Total cost 20,315,019 20,930,879 22,212,045 24,285,359 83,797,789
Alternative scenario
Symbicort Turbuhaler 9,040,183 8,581,660 8,662,697 9,107,009 33,871,520
Rilast Turbuhaler 9,040,183 8,581,660 8,662,697 9,107,009 33,871,520
DuoResp Spiromax 2,202,679 3,713,653 4,816,733 5,984,473 15,825,042
Total cost 20,283,046 20,876,974 22,142,128 24,198,492 83,568,083
Budget impact savings
-31,973 -53,905 -69,917 -86,867 -229,706
Catatonia Current scenario
Symbicort Turbuhaler 3,709,673 3,773,245 3,954,990 4,273,736 15,012,050
Rilast Turbuhaler 3,709,673 3,773,245 3,954,990 4,273,736 15,012,050
Total cost 7,419,346 7,546,491 7,909,980 8,547,472 30,024,100
Alternative scenario
Symbicort Turbuhaler 3,301,608 3,094,061 3,084,892 3,205,302 12,146,664
Rilast Turbuhaler 3,301,608 3,094,061 3,084,892 3,205,302 12,146,664
DuoResp Spiromax 803,290 1,337,001 1,712,822 2,103,255 5,640,625
Total cost 7,406,508 7,525,124 7,882,607 8,513,859 29,933,955
Budget impact savings
-12,838 -21,367 -27,373 -33,613 -90,145 
Galicia Current scenario
Symbicort Turbuhaler 7,167,402 7,341,370 7,745,338 8,418,268 29,299,579
Rilast Turbuhaler 7,167,402 7,341,370 7,745,338 8,418,268 29,299,579
Total cost 14,334,805 14,682,740 15,490,677 16,836,537 58,599,159
Alternative scenario
Symbicort Turbuhaler 6,378,988 6,019,923 6,041,364 6,313,701 23,696,070
Rilast Turbuhaler 6,378,988 6,019,923 6,041,364 6,313,701 23,696,070
DuoResp Spiromax 1,550,330 2,598,480 3,350,680 4,138,402 11,018,690
Total cost 14,308,307 14,638,327 15,433,408 16,765,805 58,410,831
Budget impact savings
-26,498 -44,412 -57,269 -70,732 -188,327 
Madrid Current scenario
Symbicort Turbuhaler 6,332,212 6,475,696 6,822,304 7,407,674 25,829,043
Rilast Turbuhaler 6,332,212 6,475,696 6,822,304 7,407,674 25,829,043
Total cost 12,664,425 12,951,393 13,644,608 14,815,348 51,658,087
Alternative scenario
Symbicort Turbuhaler 5,635,669 5,310,071 5,321,397 5,555,755 20,891,308
Rilast Turbuhaler 5,635,669 5,310,071 5,321,397 5,555,755 20,891,308
DuoResp Spiromax 1,375,782 2,302,292 2,964,526 3,657,829 9,752,800
Total cost 12,647,120 12,922,435 13,607,320 14,769,340 51,535,418
Budget impact savings
-17,304 -28,958 -37,287 -46,008 -122,669 
Valencia Current scenario
Symbicort Turbuhaler 6,427,529 6,562,282 6,902,318 7,481,939 26,151,808
Rilast Turbuhaler 6,427,529 6,562,282 6,902,318 7,481,939 26,151,808
Total cost 12,855,058 13,124,565 13,804,637 14,963,878 52,303,617
Alternative scenario
Symbicort Turbuhaler 5,720,500 5,381,071 5,383,808 5,611,454 21,154,873
Rilast Turbuhaler 5,720,500 5,381,071 5,383,808 5,611,454 21,154,873
DuoResp Spiromax 1,390,597 2,323,229 2,986,636 3,678,907 9,828,073
Total cost 12,831,599 13,085,372 13,754,253 14,901,816 52,137,820
Budget impact savings
-23,459 -39,192 -50,384 -62,062 -165,796 
Table 5 (Continued)
Madrid (7%), or Galicia (12.9%), while it is similar to 
Andalusia (9.90%) and Valencia (9.80%).14–17 Based on 
demographics, the only region where slight increases in the 
asthmatic population were observed was Andalusia (Table 4).
Asthma treatment resulted to be very costly for the 
 Spanish NHS. For instance, it has been estimated that treat-
ing patients using Symbicort Turbuhaler cost €64.21 mil-
lion in 2015. Specifically, in the base case analysis of Spain 
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before the introduction of DuoResp Spiromax, the total 
economic impact was estimated to be €524.87 million over 
4 years (Table 5). Taking into account the increasing market 
share of DuoResp Spiromax in the alternative  scenario, 
the total economic impact for Spain was calculated to be 
€523.36 million. Overall, at the national level the total budget 
savings with the market share of DuoResp Spiromax was 
expected to be €1.509 million over the next 4 years, given 
the difference in number of days of hospital stay and PC 
visits (Table 6).
This model also provides region-specific estimates. 
In the case of Andalusia, treating patients who take 
budesonide–formoterol FDC delivered by Turbuhaler 
would lead to a health care expenditure of €83.79 mil-
lion between 2015 and 2020 (Table 5). In the alternative 
scenario, costs were estimated to be €83.56 million in 
the same time period. Differences between both scenarios 
would allow Andalusia to save €229,706, which might be 
due to assumption of fewer PC visits and shorter hospital 
stays, associated with an assumption of better medication 
adherence (Tables 6 and 7). Savings of Andalusia are higher 
compared with the results of the rest of the regions included 
in this study.
Regarding Catalonia, the total economic impact of 
the current scenario was estimated to be €30.02 million, 
while in the alternative scenario, we estimated €29.93 mil-
lion over 2015–2018. Health care expenditure for asthma 
in Catalonia is the smallest one compared with the other 
regions included in this analysis. Given the results of both 
scenarios, the overall savings in Catalonia were estimated to 
be €90,145, which are obtained through reduction of health 
care resource, specifically fewer days of hospital stay and 
PC visits (Table 6).
The total economic impact without the introduction of 
DuoResp Spiromax in Galicia was estimated to be €58.59 
million between 2015 and 2018, while in the alternative 
scenario was calculated to be €58.41 million (Table 5). 
Therefore, Galicia might save €188,327, principally due 
to fewer PC visits and a small proportion of fewer days of 
hospital stay (Table 6).
Table 6 Specific results: savings due to reduction in health care resource utilization Euro 2015 (€)
Year
Regions and savings in Euros 2015 2016 2017 2018 Present value
Spain
Savings due to fewer days of hospital stay
-19,102 -32,009 -41,269 -50,982 -135,734
Savings due to avoided PC visits
-193,326 -323,956 -417,682 -515,977 -1,373,745
Total savings, Spain
-212,428 -355,965 -458,952 -566,959 -1,509,479
Andalusia
Savings due to fewer days of hospital stay
-3,434 -5,789 -7,508 -9,329 -24,668
Savings due to avoided PC visits
-28,539 -48,116 -62,408 -77,538 -205,038
Total savings, Andalusia
-31,973 -53,905 -69,917 -86,867 -229,706
Catalonia
Savings due to fewer days of hospital stay
-1,549 -2,578 -3,302 -4,055 -10,875
Savings due to avoided PC visits
-11,289 -18,789 -24,071 -29,558 -79,270
Total savings, Catalonia
-12,838 -21,367 -27,373 -33,613 -90,145
Galicia
Savings due to fewer days of hospital stay
-1,978 -3,315 -4,275 -5,280 -14,059
Savings due to avoided PC visits
-24,520 -41,097 -52,993 -65,452 -174,269
Total savings, Galicia
-26,498 -44,412 -57,269 -70,732 -188,327
Madrid
Savings due to fewer days of hospital stay
-1,961 -3,282 -4,225 -5,214 -13,901
Savings due to avoided PC visits
-15,343 -25,676 -33,062 -40,794 -108,768
Total savings, Madrid
-17,304 -28,958 -37,287 -46,008 -122,669
Valencia
Savings due to fewer days of hospital stay
-1,138 -1,902 -2,445 -3,012 -8,045
Savings due to avoided PC visits
-22,321 -37,290 -47,939 -59,050 -157,751
Total savings, Valencia
-23,459 -39,192 -50,384 -62,062 -165,796
Note: negative quantities mean savings.
Abbreviation: PC, primary care.
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Referring to Madrid, the total economic impact for the 
current scenario throughout 2015–2018 was €51.66 mil-
lion; meanwhile, the economic impact with the introduction 
of DuoResp Spiromax summed up to €51.53 million 
(Table 5). The total savings were expected to be €122,669 
over the next 4 years, given the potentially positive effect of 
DuoResp Spiromax by reducing the days of hospitalization 
and PC visits (Table 6).
Finally, with regard to Valencia, economic impact with-
out DuoResp Spiromax onto the market leads to €52.30 
million throughout 2015–2018, while economic impact with 
DuoResp Spiromax is estimated to be €52.14 million 
(Table 5). Differences between both scenarios gave total 
savings of €165,796 (Table 5). These savings might be due 
to a reduction of hospitalization resource (length of stay) and 
PC visits (Table 6).
Discussion
Treating asthma is very costly for the regional health care 
budget, given the results illustrated in Table 5. Health care 
resources used in clinical practice included drug cost, medical 
visits, hospital resource utilization, and other interventions. 
However, a potential improvement in medication adherence 
due to a more intuitive device could impact economically by 
reducing medical visits and hospital resource use. Therefore, 
any intervention that could enhance medication adherence in 
asthmatic patients would be important to lower the economic 
impact of the disease. If the inhalation technique related to 
the inhaler does not help the drug-taking pattern because 
of lack of easy-to-use design, the drug-taking history does 
not coincide with the prescribed treatment. Indeed, we took 
into account the use of different inhalers in order to quan-
tify the economic impact, keeping constant the drug effect 
(budesonide–formoterol). Finally, Turbuhaler presentations 
(Rilast and Symbicort Turbuhaler) presented higher 
proportion of errors compared to DuoResp Spiromax 
according to our expert panel.
This study compares the cost of budesonide–formoterol 
FDC delivered by two different DPIs and estimates the budget 
impact for the asthma treatment in Spain. Results suggest 
that the increasing utilization of budesonide–formoterol FDC 
delivered by Spiromax, that is DuoResp Spiromax, would 
result in a saving for the Spanish NHS of €1.509 million as 
well as savings for Andalusia, Catalonia, Galicia, Madrid, 
and Valencia of €229,706, €90,145, €188,327, €122,669, 
and €165,796, respectively.
Maintenance treatments are widely known and FDCs 
have become an advantage for controlling progression and 
symptomatology of the disease.34 As with any treatment for a 
chronic condition adherence is a requirement to achieve phar-
macological efficacy, delay the progression of the disease, 
and avoid health care resource waste. Our results suggest that 
savings for Spain and five Spanish regions are possible given 
the estimate parameters based on clinical expert consultation. 
These outcomes are in line with the results of former studies 
that investigated the relationship between nonadherence and 
the use of health care resources in a population suffering 
from a pulmonary disease.5,8,35 A proportion of events such 
as hospitalization and excessive PC visits are avoidable and 
could provide cost savings if current adherence problems are 
addressed (Table 1).
One of the strengths for our analysis is that due to the lack 
of published clinical input data from Spanish populations, 
this study was based on the real-world utilization of these 
treatments and consequences of nonadherence, considering 
that input data were based on the expert opinion of special-
ists working in different Spanish hospitals. Furthermore, our 
analysis also includes results of five representative regions 
in Spain, which allowed us to have various regions involved 
by providing input to the estimated real-world utilization. 
Differences in asthma prevalence rates are significant and, 
for instance, health care resources for treating asthmatics in 
Catalonia are lower than those expended in Galicia although 
its population is smaller than the Catalonia population. Fur-
thermore, Galicia might obtain greater savings if adherence 
improves in their population by using a more intuitive inhaler 
according to our estimations.
There are several limitations that should be noted. First, 
the model was developed to estimate the potential budget 
impact when increasing the market share of DuoResp 
Spiromax due to a reduced utilization of Symbicort 
Turbuhaler and Rilast Turbuhaler, whose FDC is 
budesonide–formoterol. This outcome may not reflect totally 
real-world change. Moreover, there are other FDCs such 
as salmeterol–fluticasone and formoterol/beclomethasone 
whose delivery system is also a DPI, for which Spiromax 
could be an alternative although we did not hypothesize 
switching prescriptions. The quantification of gains in adher-
ence leads to conservative quantities in our study, which in the 
end may be acceptable because we understand that the lack 
of adherence involves many factors,5,8,10,36 besides problems 
with the inhalation technique. Additionally, underdiagnosis 
of asthma is frequent, which is barrier for avoiding increasing 
prevalence rates of severe asthma. In Spain, underdiagnosis 
rates are high and half of the asthmatic population remains 
unaware of their condition.31 This would imply that asthma 
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health care expenditure might be even higher as only a pro-
portion of asthmatics are currently treated.
Conclusion
Enhancement of adherence is a key factor to guarantee the 
efficacy of treatment in multiple diseases, especially those 
with a chronic profile. In our study, we quantify the economic 
impact of a potential improvement in the inhalation technique 
in order to strengthen medication adherence. Results from our 
analysis suggest that an increase in utilization of DuoResp 
Spiromax, while the use of budesonide–formoterol 
FDC delivered by other devices Turbuhaler (Symbicort 
Turbuhaler and Rilast Turbuhaler) decreases, could result 
in €1.509 million decrease in the overall budget over the 
period 2015–2018. These results could also be possible in 
the five Spanish regions included in this analysis, which are 
Andalusia, Catalonia, Galicia, Madrid, and Valencia.
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